@newyorker's peptide therapy claims need context

What did @newyorker actually say?

The video is a reported piece, not a personal endorsement. A New Yorker journalist set out to test how easy it is to buy peptides without proper oversight, then sent the products to a lab. The core claim is simple: the unregulated peptide supply chain is contaminated, quality is unpredictable, and the clinical evidence for most peptides in humans is thin to nonexistent. The reporter also flagged that a 30-second telehealth consultation is not sufficient medical oversight, and that vendors demanding Bitcoin and ghosting customers is a red flag most buyers ignore.

The reporter does not claim peptides are useless across the board. The framing is more measured: "some of them might have some interesting animal studies" and "theoretical reason that they might work," but translating that to human clinical use is a different matter entirely.

Does the science back this up?

On contamination and supply quality, the lab findings are consistent with what researchers and regulators have documented. A 2023 analysis by Valisure, a pharmaceutical testing company, found that compounded and gray-market peptide products frequently fail purity and potency standards. Lead contamination in injectable products is not a minor footnote, it is a direct safety threat. Endotoxins in injectable vials can cause fever, septic shock, or death in sufficient quantities.

On clinical evidence, the reporter's expert is largely correct. BPC-157, for example, has a robust rodent literature but zero completed randomized controlled trials in humans as of early 2025. TB-500 has similar animal data and no peer-reviewed human trial data. MOTS-c, the peptide sourced from Gary Brecka's platform, has early human pharmacokinetic data (Lee et al., 2015, Cell Metabolism) showing it influences insulin sensitivity, but nothing resembling a clinical efficacy trial. The leap from "interesting mechanism" to "inject this into yourself" is real, and the video is right to call it out.

What did they get wrong (or right)?

The reporter gets the contamination story right, and that deserves credit. The FDA warning letter to Swiss Chems (the video calls it "Swiss Kems" and "Swiss Camps," likely transcription artifacts) is a matter of public record. The framing of a 30-second telehealth consult as inadequate is also defensible, though it glosses over variation in telehealth quality. Not every telehealth provider operates this way.

Where the video is incomplete: it treats all peptides as a single category. GHK-Cu, for instance, has a more developed topical safety profile than injectable BPC-157. Lumping them together as equally unproven oversimplifies. The video also does not distinguish between FDA-approved peptides (semaglutide, tesamorelin, oxytocin) and completely unapproved ones, which matters for a viewer trying to make sense of the regulatory picture. The claim that MOTS-c was "98% pure" is presented as reassuring, but purity alone says nothing about biological activity, stability, or sterility, a point the reporter does acknowledge briefly.

What should you actually know?

The contamination findings are the most actionable part of this story. Lead and endotoxins in injectable vials are not theoretical risks. Anyone sourcing peptides from unregulated vendors is running a real safety gamble, not just an efficacy one. The FDA does not test gray-market peptides before they reach consumers, and "research use only" labeling is widely understood to be a legal shield, not an accurate description of how these products are used.

The clinical evidence gap is also real, but it is not permanent. Several peptide compounds are in or approaching clinical trials. Dismissing the entire class as pseudoscience is not accurate either. What is accurate is that self-directing injectable peptide protocols based on TikTok videos and biohacker podcasts, without proper medical oversight and a verified pharmaceutical-grade supply, carries risks that most content in this space does not address honestly.

• Source peptides only through licensed compounding pharmacies operating under USP 797 sterile compounding standards if a physician has prescribed them.
• A 30-second telehealth consult does not meet the standard of care for prescribing injectable compounds.
• Purity percentage alone is not a safety guarantee for injectables. Sterility, endotoxin testing, and potency verification are separate requirements.